Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Verrica Pharmaceuticals, Inc.

https://verrica.com/

Latest From Verrica Pharmaceuticals, Inc.

Keeping Track: US FDA Is Approving JAK Inhibitors Again, Starting With Incyte’s Opzelura; Seagen’s Tivdak Cleared

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Asia Deal Watch: Takeda Keeps Up Hectic Deals Pace Via Three New Alliances

Takeda pursues RNA-targeting R&D with Evotec and Anima, looks into liver disease with Genevant. Plus deals involving Kyowa Kirin/Twist, Bright Peak/Ajinimoto & Torii/Verrica.

Deals Business Strategies

Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Approvals Biosimilars

Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers

Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.

Deals Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register